Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Ardelyx, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ardelyx, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How ARDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-10-25 | XPHOZAH® (tenapanor) | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| IBSRELA | |||
| XPHOZAH |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenapanor Small MoleculesNCT07382167 | Chronic Idiopathic Constipation (CIC) | Phase 3 | RECRUITING | 692 | Jun 4, 2027 | ||||||
| Tenapanor Small MoleculesMarketedNCT06553547 | Irritable Bowel Syndrome With Constipation (IBS-C) | Approved | COMPLETED | 402 | Jul 7, 2026 | ||||||
| Tenapanor Small MoleculesMarketedNCT02081534 | Hyperphosphatemia | Approved | COMPLETED | 2,176 | Nov 1, 2014 | ||||||
| Tenapanor Small MoleculesMarketedNCT02686138 | Constipation Predominant Irritable Bowel Syndrome | Approved | COMPLETED | 1,867 | Oct 1, 2017 | ||||||
| Tenapanor Small MoleculesMarketedNCT01847092 | Chronic Kidney Disease | Approved | COMPLETED | 154 | Apr 1, 2015 | ||||||
| Tenapanor Small MoleculesNot countedNCT01764854 | End Stage Renal Disease | Phase 2 | COMPLETED | 88 | Oct 1, 2013 | ||||||
| Tenapanor Small MoleculesNot countedNCT06203444 | Lactation | Phase 1 | COMPLETED | 7 | May 30, 2024 | ||||||
| RDX013 Small MoleculesCompletedNCT04780841 | Hyperkalemia | Phase 2 | COMPLETED | 109 | Mar 3, 2022 | ||||||
| RDX5791 Small MoleculesMarketedNCT01340053 | Constipation Predominant Irritable Bowel Syndrome | Approved | COMPLETED | 186 | Feb 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IBSRELA | Irritable Bowel Syndrome with Constipation (IBS-C) | 2026-10-12 | 4.5 to 3.0Read More | Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hohenleitner SusanOfficer (Chief Financial Officer) | Sell | -1,558 227,520 held | $3.86 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1.4 % | 30.94 M | 9.05 M |
Ownership Trends
ARDX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ARDX ranks across every disease it competes in
ARDX News
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Ardelyx Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026. The event will be accessible via a live webcast. Ardelyx focuses on innovative medicines and has two approved products, with ongoing Phase 3 development for IBSRELA.
Read more →Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
Ardelyx reported a total product revenue of $125.5 million for Q3 2026, marking a 19% increase from the previous year. The revenue from IBSRELA reached $96.3 million, growing 23% year-over-year. The company completed enrollment for its Phase 3 ACCEL trial for chronic idiopathic constipation ahead of schedule and maintains a strong cash position of $285.3 million.
Read more →Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
Ardelyx has fully enrolled patients in the Phase 3 ACCEL trial for IBSRELA (tenapanor) ahead of schedule. This trial aims to evaluate the drug's efficacy for chronic idiopathic constipation in adults, with topline data expected in the second half of 2027. The company emphasizes the need for new treatment options for patients suffering from this condition.
Read more →Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Ardelyx presented real-world data at ASN Kidney Week 2026 showing XPHOZAH reduced serum phosphate in dialysis patients. The analysis of 1,400 adults found adjusted mean reductions of 0.80 to 1.55 mg/dL at six months. Sixty to 70 percent of patients remained on tenapanor at 180 days. The data reinforce ongoing challenges in managing hyperphosphatemia.
Read more →Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
Ardelyx Inc. has announced a conference call scheduled for November 3, 2026, to discuss its third quarter financial results and provide a business update. The call will be accessible via a live webcast, with an archived replay available afterward. Ardelyx continues to focus on developing innovative treatments for unmet medical needs.
Read more →Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
Ardelyx, Inc. presented real-world data at ACG 2026 showing a significant decrease in gastrointestinal-related healthcare resource utilization after adults with IBS-C started treatment with IBSRELA (tenapanor). The analysis involved 470 patients and indicated a drop in healthcare visits from 4.5 to 3.0 per year. Additional data on IBS-C symptom burden and an ongoing Phase 3 study were also discussed.
Read more →Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Ardelyx, Inc. announced the presentation of three abstracts at ASN Kidney Week 2026, focusing on hyperphosphatemia management. The research includes real-world effectiveness of tenapanor, patient perspectives, and morbidity risks associated with hyperphosphatemia. Additionally, an Exhibitor Spotlight session will feature insights on XPHOZAH, a phosphate absorption inhibitor for CKD patients on dialysis.
Read more →Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
Ardelyx, Inc. announced its recognition at the 2026 PM360 Trailblazer Awards, where it received multiple honors including Life Sciences Manufacturer CEO of the Year for Mike Raab. The company was also acknowledged for its podcast 'Gut Matters' and the IBSRELA Marketing Team. These awards highlight Ardelyx's commitment to innovation and patient engagement.
Read more →Ardelyx to Participate in Upcoming Investor Conferences
Ardelyx Inc. has announced its participation in several upcoming investor conferences in September 2026. The conferences include Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, and Morgan Stanley's Global Healthcare Conference, all taking place in New York. The company will provide live webcasts of the fireside chats and has a strong product pipeline.
Read more →Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Ardelyx reported a strong financial performance for Q2 2026, with total product revenue reaching $118.1 million, marking a 31% increase compared to the previous year. The revenue from IBSRELA grew by 33% to $86.2 million, while XPHOZAH also saw a 27% increase to $31.9 million. The company maintains a robust cash position of $281.8 million.
Read more →Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Ardelyx, Inc. announced a conference call scheduled for August 6, 2026, to discuss its second quarter financial results and provide a business update. The event will be accessible via a live webcast and will include an archived replay. Ardelyx is known for its focus on innovative medicines and has two approved products in the U.S.
Read more →Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Ardelyx Inc. announced its participation in the Jefferies Global Healthcare Conference 2026, scheduled for June 3 at 9:55 a.m. ET in New York. The company will engage in a fireside chat, which will be accessible via a live webcast. Ardelyx is known for its innovative medicines and has two approved products in the U.S.
Read more →Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
Ardelyx presented a data analysis at the NKF Spring Clinical Meetings, showcasing the long-term safety of XPHOZAH (tenapanor) for managing serum phosphorus in chronic kidney disease patients on dialysis. The analysis indicated no clinically meaningful changes in serum electrolytes, reinforcing the drug's effectiveness. A peer exchange session will further discuss XPHOZAH's mechanism and safety data.
Read more →Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Ardelyx Inc. reported its financial results for Q1 2026, highlighting a significant increase in total product revenue and continued robust growth for IBSRELA. The company's revenue for IBSRELA amounted to $70.1 million, driven by increased prescription demand. Despite a strong financial position, Ardelyx reported a net loss of $37.6 million during the quarter. The company is focused on advancing its pipeline, including ongoing clinical trials for IBSRELA and the development of the next-generation NHE3 inhibitor, RDX10531.
Read more →Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Ardelyx, Inc. announced that an abstract detailing the long-term effects of XPHOZAH on serum electrolytes will be presented at the NKF Spring Clinical Meetings in May 2026. XPHOZAH is the first phosphate absorption inhibitor approved for adults with chronic kidney disease on dialysis. The company will also sponsor a peer exchange discussing XPHOZAH's efficacy and safety.
Read more →Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
Ardelyx, Inc. announced that an abstract exploring treatment patterns for irritable bowel syndrome with constipation (IBS-C) has been accepted for a poster presentation at the Digestive Disease Week Conference 2026. The company will also sponsor a Product Theater discussing IBS-C management strategies. IBSRELA, Ardelyx's treatment for IBS-C, has shown promise in improving symptoms.
Read more →Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Ardelyx, Inc. has appointed Felecia W. Ettenberg as Chief Legal Officer, succeeding Elizabeth Grammer. Ettenberg brings over 25 years of legal experience in the biopharmaceutical sector, including a significant tenure at Bristol Myers Squibb. The company aims to leverage her expertise to enhance its legal, compliance, and regulatory operations while continuing to focus on patient needs.
Read more →Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Ardelyx, Inc. announced a conference call for April 30, 2026, to discuss its first quarter financial results and provide a business update. The event will be accessible via a live webcast on the company's website. Ardelyx is known for its innovative medicines, including two approved products and ongoing Phase 3 development.
Read more →Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Ardelyx, Inc. has appointed Dr. Rajani Dinavahi as Chief Medical Officer. With over 20 years of experience in various therapeutic areas, she aims to strengthen the company's pipeline and enhance its medical capabilities. Dr. Dinavahi expressed enthusiasm about joining Ardelyx during a pivotal time for the company.
Read more →Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Ardelyx, Inc. announced the recipients of the 2026 Derek Forfang Patient Advocate Award, honoring individuals who have significantly contributed to advocating for kidney disease patients. Established in 2025, the award commemorates Derek Forfang, a dedicated advocate who passed away due to chronic kidney disease. The recipients include notable figures like Edward Drake II and Markesha Grayson, each recognized for their impactful work in educating and supporting communities. The award presentation will take place at the National Kidney Foundation's Spring Clinical Meetings in New Orleans.
Read more →